MedPath

Ottawa Hospital Research Institute

Ottawa Hospital Research Institute logo
🇨🇦Canada
Ownership
Private
Established
2001-01-01
Employees
5K
Market Cap
-
Website
http://www.ohri.ca

More Frequent Screening with Pressure-Supported SBTs May Extend Time to Successful Extubation

• A recent study investigated the impact of screening frequency and spontaneous breathing trial (SBT) techniques on successful extubation in mechanically ventilated adults. • The trial found no significant differences in time to successful extubation based on screening frequency or SBT technique alone. • An interaction showed that more frequent screening combined with pressure-supported SBTs increased the time to successful extubation. • Once-daily screening with pressure-supported SBTs was associated with a shorter time to first successful SBT, suggesting a potential benefit.

Tranexamic Acid Fails to Reduce Transfusions in Radical Cystectomy: TACT Trial

• A randomized, double-blind, placebo-controlled trial (TACT) assessed tranexamic acid (TXA) in patients undergoing radical cystectomy for bladder cancer. • The study found that TXA did not significantly reduce the need for red blood cell transfusions within 30 days post-surgery compared to placebo. • Secondary outcomes, including blood loss and thromboembolic events, also showed no significant differences between the TXA and placebo groups. • The findings suggest that routine use of TXA during open radical cystectomy for bladder cancer is not recommended.

VITdALIZE-KIDS Trial Assesses Vitamin D Supplementation Impact on Pediatric ICU Patients' Quality of Life

• The VITdALIZE-KIDS trial is a phase III, multicenter, randomized, double-blind study evaluating high-dose vitamin D supplementation in critically ill children with vitamin D deficiency. • The primary outcome is health-related quality of life (HRQL) measured by the PedsQL™ scale at 28 days post-intervention, with secondary outcomes including hospital length of stay and adverse events. • The trial aims to enroll 766 patients across 11 Canadian PICUs, randomizing them to either a high-dose cholecalciferol bolus or a placebo, with a metabolomics sub-study planned for a subset. • Interim analyses are scheduled to assess efficacy and safety, with a DSMB providing oversight and the potential for early termination based on futility or safety concerns.
© Copyright 2025. All Rights Reserved by MedPath